^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EpCAM inhibitor

    Related drugs:
    18h
    Evaluation of leukocyte depletion filters for the removal of EpCAM-positive tumor cells during oncologic intraoperative blood salvage using CATUVAB®: an exploratory feasibility study. (PubMed, BMC Anesthesiol)
    The present study demonstrates that the CATUVAB® procedure, in combination with different leukocyte depletion filters, achieved effective removal of EpCAM-positive tumor cells, accompanied by low residual catumaxomab levels and reduced pro-inflammatory cytokine concentrations. These findings support the feasibility of this approach; however, given the limited sample size and exploratory design, they should be considered preliminary and require confirmation in larger studies.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    CD33 positive
    |
    Korjuny (catumaxomab)
    1m
    Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC. (PubMed, BMC Cancer)
    IRDye800CW-labeled anti-EpCAM antibodies allow experimental microscopic delineation of HNSCC from non-malignant tissue. As a future outlook, these probes might improve tumor resection in near-infrared fluorescence-guided surgery of primary and recurrent HNSCC.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    adecatumumab (MT201)
    1m
    M70103: A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Wuhan YZY Biopharma Co., Ltd. | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial primary completion date
    |
    cisplatin • M701
    1m
    Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody (clinicaltrials.gov)
    P3, N=312, Active, not recruiting, Wuhan YZY Biopharma Co., Ltd. | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    M701
    2ms
    Safety of AM-928 Infusion in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, AcadeMab Biomedical Inc. | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    AM-928
    4ms
    BNT314-02: A clinical study to test if an investigational treatment called BNT314 when used in combination with another investigational treatment BNT327 and chemotherapy is beneficial and safe for patients with advanced colorectal cancer (2025-521768-36-00)
    P1/2, N=168, Recruiting, BioNTech SE
    New P1/2 trial
    |
    MSI (Microsatellite instability)
    |
    pumitamig (BNT327)
    5ms
    A Study of KK2269 in Adult Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=101, Recruiting, Kyowa Kirin Co., Ltd. | N=71 --> 101 | Trial completion date: Dec 2027 --> Mar 2029 | Trial primary completion date: Dec 2027 --> Mar 2029
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    docetaxel
    5ms
    Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, BioNTech SE | Trial completion date: Sep 2026 --> Mar 2028 | Trial primary completion date: Sep 2026 --> Jun 2027
    Trial completion date • Trial primary completion date • First-in-human
    8ms
    Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting | N=103 --> 41
    Enrollment closed • Enrollment change • First-in-human
    9ms
    Near-Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-EpCAM Antibody. (PubMed, Cancer Sci)
    The fully human monoclonal antibody targeting EpCAM, adecatumumab, was conjugated with the photosensitizer IR700 at different dye-antibody ratios (DAR2, DAR4, DAR7) and tested on OE19 cells and xenograft mouse models under near-infrared light irradiation...Notable EpCAM expression and homogeneity underpin EpCAM as a promising target for NIR-PIT in EGJ adenocarcinoma. The fully human anti-EpCAM antibody may be suitable for NIR-PIT in EGJ adenocarcinoma.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    adecatumumab (MT201)
    9ms
    Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. (clinicaltrials.gov)
    P1, N=168, Recruiting, BioAtla, Inc. | Trial completion date: Dec 2025 --> Sep 2028 | Trial primary completion date: Jun 2025 --> Sep 2028
    Trial completion date • Trial primary completion date
    10ms
    BNT314-02: A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=482, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • pumitamig (BNT327)